The National Cancer Institute funds cancer epidemiology cohort research on cancer causes and survivorship, including cohort upkeep, follow-up, and data and biospecimen sharing; clinical trials are not allowed.
Funder: National Institutes of Health
Due Dates: February 5, 2027 (New) | March 5, 2027 (Resubmission) | June 5, 2027 (New) | July 5, 2027 (Resubmission) | October 5, 2027 (New) | November 5, 2027 (Resubmission) | February 5, 2028 (New) | March 5, 2028 (Resubmission) | June 5, 2028 (New) | July 5, 2028 (Resubmission) | October 5, 2028 (New) | November 5, 2028 (Resubmission) | February 5, 2029 (New) | March 5, 2029 (Resubmission) | June 5, 2029 (New) | July 5, 2029 (Resubmission / Closing)
Funding Amounts: No budget cap; requests must reflect project needs; maximum project period of 5 years; no cost sharing required
Summary: NCI supports cancer epidemiology cohorts addressing knowledge gaps in cancer etiology and survivorship through research, cohort development, follow-up, and resource sharing.
Key Information: Clinical trials and infrastructure-only proposals are not allowed.
The National Cancer Institute (NCI) supports prospective cancer epidemiology cohort studies through this U01 cooperative agreement. The program funds hypothesis-driven research within established cohorts, science-driven expansion of recently formed cohorts, and formation of new cohorts. Risk cohorts follow individuals without a history of cancer for new cancer incidence; survivor cohorts follow people diagnosed with cancer for cancer-related and other outcomes.
Projects must address important scientific gaps in cancer risk or survivorship. Infrastructure support for established cohorts must directly serve the proposed research aims. New cohorts must establish a clear scientific vision and demonstrate recruitment and retention feasibility. The program emphasizes community partnerships, continued participant follow-up, sustainable cohort resources, and broad sharing of data and biospecimens to advance cancer prevention and control.